709 results about "Hyperuricemia" patented technology

The present invention discloses two crystal models and the preparation method of the anti-hyperuricemia drug 2-(3-ayano-4-isobuoxy phenyl)-4-methyl-5- thiazole acid. The preparation method of the crystal models commonly uses the low-toxicity ethanol, ethyl acetate or acetone as the solvent; the safety is relatively high. In addition, the hygroscopicity of the two crystal models is low in the high-humidity environment and the two crystal models are suitable for the steady pharmaceutical preparation.

The invention belongs to the chemical field of natural products and particularly relates to a preparation method and use of moringa oleifera leaf polysaccharides. The preparation method comprises the steps of carrying out combined microwave-ultrasound extraction, hydrochloric acid method deproteinization, hydrogen peroxide method decoloration and AB-8 macroporous adsorption resin column separation, so as to prepare the moringa oleifera leaf polysaccharides. The preparation method of the moringa oleifera leaf polysaccharides has the advantages of short extraction time, low extraction temperature, low energy consumption and high extraction rate and purity. Besides, an animal experiment proves that the prepared moringa oleifera leaf polysaccharides have remarkable treatment effect to hyperuricosuria; by decreasing the content of cholesterol, triacylglycerol, urea nitrogen, creatinine and xanthine oxidase, the production of uric acid is achieved; meanwhile, by directly decomposing uric acid, renal functions are improved, the excretion of uric acid is promoted, and blood vessels are protected, thereby being favorable to the recovery of patients with the hyperuricosuria. The preparation method has a wide medical application prospect.

An extract of mulberry twigs is dislcosed, which can be used to prepare the food or the medicine to cure hyperuricemia and gout diseases. The said extract is prepared from mulberry twigs through extracting in solvent (aqueous solution of alcohol, chloroform, acetone, etc) at 10-100 deg.C more than one time, mergint the liquid extracts, recovering solvent, regulating pH value to 7.5-9.5, centrifugal separation to obtain supernatant, regulating pH value to 4-6, deposition, water washing wand drying. Several other approaches for purifying it are also disclosed.

The invention relates to application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout and further provides medicine or health-care food for treating hyperuricemia and gout. Celery seed extract serves as the active constituent, and an appropriate number of medical carriers or auxiliary constituents are added, so that a preparation is obtained. The medicine for health-care food is simple in preparation process, the celery seed extract can obviously lower serum uric acid of model mice suffering from hyperuricemia caused by oteracil potassium salt, lower the activity of xanthine oxidase to different degrees, achieve an obvious inhibition effect on arthritis of the mice, prevent and treat hyperuricemia or gout and be applied to preparation of the medicine or health-care food for resisting to hyperuricemia and gout.

The invention discloses special dietary seafood special for hyperuricemia patients. The seafood is characterized by being prepared by taking food-derived marine bioactive polysaccharides as main raw materials, adding algae powder and mixing the food-derived marine bioactive polysaccharides and the algae powder with the auxiliary materials including nutritional amino acids, oligosaccharides, vitamins and minerals. The seafood can be powdery or granular and is eaten after being dissolved in warm water. The seafood is easy to dissolve, has maximum biological absorbance and maximum bioavailability in human bodies, provides marine active factors and nutritional components for human bodies, supplements various vitamins and minerals essential to human bodies, is beneficial to improving the nutritional status of the hyperuricemia patients and can assist in reducing the uric acid level and controlling the hyperuricemia level, improving the immune of the human bodies and preventing gout throughsynergy of such factors as bioactive components in the food-derived marine bioactive polysaccharides, the algae powder, the nutritional amino acids and the like, thus being suitable for the hyperuricemia patients.

A compound represented by following general formula (I):wherein, represents a single bond or a double bond; L represents —NH— or the like; X1 represents N or C, provided that in the case where X1 is N, X2 represents C—R and in the case where X1 is C, X2 represents N—R1 or the like; Y's may be either the same or different and represent CH2 or the like; A represents a non-natural sugar residue represented by following general formula:wherein, m represents 0 to 1; represents a single bond or a double bond; X represents O or the like; R3 to R8 may be either the same or different and represent hydroxy group or the like; and B represents a group represented by following general formula:wherein, n and k represent 0 to 5; represents a single bond or a double bond; Z1 to Z16 may be either the same or different and represent CH or the like; R10 and R11 may be either the same or different and represent a lower alkoxy group having 1 to 5 carbon atoms or the like; and R15 represents a hydrogen atom or the like, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or solvate thereof. Because of having an excellent CNT2 inhibitory activity and showing a high in vivo stability and stable physicochemical properties, the aforesaid compound is useful as a remedy for hyperuricemia.

The invention belongs to the field of pharmacogenomics and genetic diagnosis, and relates to a method used for detecting HLA-B*5801 alleles. The method comprises following steps: a DNA sample to be detected is taken, three pairs of specific primers and a pair of internal primers are taken, amplification of DNA segments is realized by using sequence specific primer method, and then the results of the amplification are analyzed by agarose gel electrophoresis; or sample DNA is extracted, a pair of specific primers, a pair of internal primers and three fluorescence probes are taken, amplification of DNA segments is realized by Taqman probe method using a fluorescence ration PCR instrument, and then the amplification curve is analyzed so as to obtain results. Results analysis methods such as agarose gel electrophoresis, high resolution melting curve and SYBRGreen fluorogenic quantitative PCR are employed in the method. The method has advantages of speediness, convenience, flexibility, high resolution and no contamination; is suitable for detection of HLA-B*5801 alleles in samples such as peripheral blood and hair; and can be used for determining the probability of severe skin adverse reaction of patients with gout or hyperuricemia caused by taking of allopurinol.

A novel 1,2,4-triazole compound which is useful as a therapeutic agent for hyperuricemia and gout due to hyperuricemia is provided. A compound is represented by the following general formula (1):wherein R2 represents an unsubstituted or substituted pyridyl group, R1 represents a similar pyridyl group, a pyridine-N-oxide group corresponding to these pyridyl groups, or a phenyl group, and R3 represents hydrogen or a lower alkyl group substituted with pivaloyloxy group and R3 bonds to a nitrogen atom in the ring. A process for production of a compound by reacting a nitrile and a hydrazide, and a therapeutic agent, particularly a xanthine oxidase inhibitor are also provided.

A composition composed of a Lactobacillus bacterium, Bifidobacterium longum, and xylooligosaccharide is provided for use in reducing uric acid levels in the blood and preventing or treating hyperuricemia or gout.

The invention disclosed an aryl nitrile group thiazole derivative for inhibiting the activity of xanthine oxidase, a method for preparing the same and application thereof. In the aryl nitrile group thiazole, R1 is methyl, ethyl, propyl, isopropyl, isobutyl, methyl cyclopropane, methyl cyclobutane, isoamyl, methyl cyclopentane, methyl cyclohexane or aromatic ring methyl, R2 is methyl or trifluoromethyl, and R3 is formic acid, sodium formate, potassium formate, lithium formate, methyl formate, or ethyl formate. Simultaneously, the invention discloses a method for synthesizing the aryl nitrile group thiazole derivative by using inexpensive raw materials, which has the advantages of simple operation, high yield, easy purification of products, application to industrial production and the like, and can obtain an efficient compound with low toxicity through screening; besides, the effective compound is expected to be widely applied to inhibit the activity of the xanthine oxidase required on animals and humans, and to become a new generation of antigout drugs and hyperuricemia drugs with special effect.

The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.

Provided is an enteric preparation for preventing and curing hyperuricemia and gout. The employing essential component of the preparation is enteric capsules of uricase. The causes of the hyperuricemia and the gout are that uric acid is over generated and / or the uric acid is diminished in discharging, and metabolic diseases increasing the density of serum uric acid. About one third of the uric acid of the human body is defecated from intestinal canals, and the uric acid entering the canals still can be reabsorbed. When the hyperuricemia and the gout happen, the proportion of the uric acid defecated from the intestinal canals is increased. The uricase is capable of rapidly effectively dissociating the uric acid. The uricase of the enteric preparation after being orally taken is disintegrated in the intestinal canals and is diffused from blood into the uric acid of the intestinal canals, preventing the uric acid from reabsorbing, thereby reducing the density of the serum uric acid, achieving the purposes of preventing and curing the hyperuricemia and the gout. The oral uricase has the characteristics of non-absorbent property by the intestinal canals, keeping out of blood circulation, no producing of antibodies of organisms and allergic response, providing a new method for preventing and curing the hyperuricemia and the gout.

The invention discloses substitutional tea with the uric acid reducing effect and a preparation method thereof. The substitutional tea is prepared from the following raw materials in parts by weight:10-60 parts of chicory, 40-110 parts of corn stigma, 20-100 parts of radix puerariae, 1-12 parts of rhizoma polygonati, 1-15 parts of poria cocos, 0.1-2 parts of celery seeds, 1-10 parts of emblic leafflower fruits, 300-500 parts of semen coicis, 0.5-3 parts of marine fish oligopeptide, 0.5-3 parts of seaweed extract, 0.5-3 parts of cherry powder, 30-80 parts of fructus momordicae grosvenori, 20-70 parts of fructus crataegi, 10-35 parts of horseradish tree leaves, 20-60 parts of cranberries and 20-80 parts of honeysuckle flower, wherein part of the raw materials are extracted and then granulated and are mixed and packaged with other raw materials so as to form the substitutional tea. The substitute tea with the uric acid reducing effect has the advantages that the raw materials such as leaves, rhizomes, flowers, fruits, seeds and functional factors of a food source are scientifically proportioned, aiming at different forming reasons of uric acid, adjuvant materials are not added, in addition, the use is convenient, the taste is good, the substitutional tea has no toxic and side effects after being drunk for a long time, is suitable for being drunk by people suffering from hyperuricemia for a long time and has very good uric acid reducing effect.

The invention provides chimeric protein of mammal-derived uricase which contains part of humanized uricase amino acid sequences and has enzymatic activity and mutant protein thereof, a deoxyribonucleic acid (DNA) sequence encoding the chimeric protein, a carrier containing the DNA sequence, a host cell containing the carrier, a method for preparing the chimeric protein and the mutant protein thereof by genetic engineering and a medicinal composition. The chimeric protein and the mutant protein reserve the activity of the mammal-derived uricase, can reduce immunogenicity suitable for human bodies and enhance or improve the physicochemical property of mammal source uricase protein simultaneously, and are suitable for treating hyperuricemia and gout caused by the hyperuricemia.

The invention relates to a traditional Chinese pharmaceutical composition for treating gout and its preparing process, wherein the composition is prepared from sharpleaf galangal fruit, corktree bark, ash bark, polyporus umbellatus, oriental water plantain rhizome, plantain herb, coralbean bark, root of bidentate achyranthes, raw material and medicinal adjuvant. The composition can be prepared into various pharmaceutically acceptable oral preparations.

The invention discloses lactobacillus rhamnosus NX-2 and an application thereof in preparation of uric acid reducing drugs, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus NX-2 disclosed by the invention has a preservation number of CGMCC No.20110. Non-inactivated and inactivated fermentation supernate, bacterial suspension and cell disruption material supernate of the lactobacillus rhamnosus NX-2 have uric acid reducing effects on a zebrafish high-uric-acid model, and can inhibit the activity of xanthine oxidase in the body of a high-uric-acid zebrafish. Thelactobacillus rhamnosus NX-2 disclosed by the invention has a huge potential application prospect in the aspect of preparing medicines for treating and / or preventing hyperuricemia.

The invention belongs to the field of medicines and discloses a mango leaf extract and application thereof. Mango leaves are subjected to refluxing extraction and concentration via aliphatic alcohol with 1-4 carbon atoms, and the obtained product is extracted and purified via low-polarity organic solvent and is refined to obtain the mango leaf extract. The mango leaf extract disclosed by the invention contains mangiferin and homomangiferin which are at specific proportion, and is better than a mangiferin monomer in the solubility. Pharmacological research proves that the mango leaf extract has the effects of lowering the level of serum uric acid of a hyperuricemia mice and reducing blood sugar, and is better than the mangiferin. Therefore, the invention provides application of the mango leaf extract provided by the invention to the medicine for preventing or treating the metabolic syndrome.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention relates to an application of Graveobioside A in the preparation of drugs or healthcare food for preventing hyperuricemia and gout. The invention also provides a drug or healthcare food for treating hyperuricemia and gout. Graveobioside A is the active component and is mixed with a proper amount of pharmaceutical carrier or excipient to prepare preparations. Graveobioside A can prominently reduce uric acid in serum of an oteracil potassium caused hyperuricemia model mouse, reduces the activity of xanthine oxidase at different levels, and prominently inhibit the arthritis of mouse. Graveobioside A can treat and prevent hyperuricemia and gout and can be used to prepare drugs or healthcare food for preventing hyperuricemia and gout.

The invention relates to use of vegetable extract in inhibiting xanthine oxidase (XO) and application in preparing food for preventing and treating hyperuricemia or gout. The vegetable extract is prepared by the following steps: a methanol extraction process: removing impurities from fresh vegetable, and removing moisture in an electrothermal blowing drying box at 40 DEG C; crushing the vegetableinto powder by a crusher; weighing a certain amount of dry vegetable into a conical flask, and extracting by methanol ultrasonic wave twice for 45 minutes in each extraction; filtering to remove the filter residue; recycling the solvent from the filtrate by a rotary evaporator, and drying the remainder in an electrothermal vacuum drying box to obtain extractum; and applying the vegetable methanolextract to an in vitro XO inhibition test so as to screen out the vegetable crude extract with the effect on inhibiting the XO. The invention provides an reference on diet for preventing and treatinggout or hyperuricemia.

The present invention relates to 5-Aryltetrazole compounds, compositions comprising a 5-Aryltetrazole compound, and methods for treating an inflammation disease, a reperfusion disease, hyperuricemia, gout, or tumor-lysis syndrome in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.

The invention belongs to the technical field of medicines, relates to eurycoma longifolia Jack extract and eurycomanone and a preparation method thereof, and also relates to use of the eurycomanone and the eurycoma longifolia Jack extract and a composition containing the eurycomanone and the eurycoma longifolia Jack extract in preparing of anti-tumor, anti-gout and anti-hyperuricemia drugs, health food, functional food and food. The eurycoma longifolia Jack extract is obtained by taking a dry eurycoma longifolia Jack medicinal material, extracting with water or alcohol, concentrating liquid extract, recovering a solvent and drying. The eurycomanone is obtained by using a solvent for gradient elution of the eurycoma longifolia Jack extract by silica gel column chromatography. Refined high purity target compound eurycomanone can be obtained by recrystallization treatment when necessary (when the eurycomanone contains a small amount of impurities or pigments and the like).

The invention discloses application of cannabinoids in the preparation of a medicine for treating gout. The inventor found for the first time that cannabinoids have a very strong antigout effect, can significantly reduce serum urate level of hyperuricemia mice but have no remarkable influence on serum urate level of normal mice, can substantially inhibit toe swelling induced by sodium urate, have more excellent activity than allopurinol and have little toxic and side effect. The invention also provides a gout-treating medicinal preparation of the cannabinoids and a corresponding dosage form. By a conventional preparation method, various different dosage forms of medicines used in clinic can be prepared and are convenient to use.

The invention provides an effective part of chicory (or jerusalem artichoke) for preventing and curing hyperuricemia and a preparation thereof, wherein the effective part is prepared by the following method comprising the following steps of: extracting the chicory (or the jerusalem artichoke) with water for 1-5 times with 3-20 times of water at each time, wherein the extracting time at each time is 0.5-2.5 hours; and precipitating a chicory (or jerusalem artichoke) water extract with 40-percent ethanol, filtering and recovering the ethanol to obtain the 40-percent amylose effective part. The effective part has definite curative effect in the aspects of preventing and curing the hyperuricemia, can be used for preventing and curing the hyperuricemia, the hyperuricemia plus hypertriglyceridemia, the hyperuricemia plus hyperglycemia and the hyperuricemia plus blood hypercoagulation and blood hyperviscosity and has no obvious toxic or side effect or adverse reaction.

The invention provides sunflower head extract prepared by a crystallization enzymolysis method and a preparation method of the sunflower head extract. A sunflower head is a pure natural traditional Chinese medicine or a material both used as medicine and food; the sunflower head is scientifically extracted to prepare a functional health product both used as medicine and food, which has the effects of resisting gout, treating hyperuricemia, improving the immunity, lowering blood glucose and blood lipid, protecting kidney and liver, eliminating swelling, resisting inflammation and relieving pain and has the effects of dissolving uric acid calculus, lowering serum uric acid concentration, eliminating swelling and resisting inflammation, adjusting purine and uric acid metabolism, balancing in-vivo acid-base equilibrium and balancing in-vivo hormones; the product is safe, has no side effect, has remarkable health effect and can be eaten for a long period, so that a market development prospect is very good.

The invention belongs to the field of medicinal chemistry and particularly relates to hURAT1 (human urate anion transporter 1) inhibitors and an application thereof. Specifically, the hURAT1 inhibitors are compounds with structure shown as formula (I) or (II) in the description or pharmaceutically acceptable salts of the compounds. Experiments prove that the compounds have good inhibition effect on uric acid transport of the hURAT1 in an HEK293 transfection cell, which shows that the compounds have good application prospect in treatment of hyperuricemia or gout.

The present invention is directed to certain novel triazole compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof. The present invention is also directed to methods of making and using such compounds and pharmaceutical compositions containing such compounds to treat or control a number of diseases mediated by PPAR such as glucose metabolism, lipid metabolism and insulin secretion, specifically Type 2 diabetes, hyperinsulemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for cardiovascular disease, Syndrome X, hypertriglyceridemia, hyperglycemia, obesity, and eating disorders.

The invention relates to a traditional Chinese medicinal preparation used for preventing and treating hyperuricemia and a combination thereof, which are respectively formulated by amur corktree, Chinese actractylodes, glabrous greenbrier rhizome and honeysuckle stem by weight proportion, or formulated by certain weight of extract alkaloids, ligroine, saponin and flavone thereof.Wherein, the method of the medicinal preparation is that: after the Chinese actractylodes, the amour corktree, the glabrous greenbrier rhizome and the honeysuckle stem are mixed, ethanol is used for extracting thereof; concentration solution is obtained by recycling the ethanol; then the medicinal preparation is made.The alkaloids is extracted from the Chinese atractylodes by steam distillation; extractable fluid and dregs are obtained from the glabrous greenbrier rhizome and honeysuckle stem by using acetone; extract is obtained by recycling the acetone in the extractable liquid; after the extract is dissolved by alkali, organic acid is prepared by replacing anionic with resin to be depurated; the saponin and the flavone are obtained by using alcohol extract and n-butanol extract to purify the dregs; at last, the medicine is prepared by certain proportion. The medicine provided by the invention has significant hypouricemic activity.

The present invention relates to methods for preventing the progression of joint damage in a subject having hyper-uricemia and who has gout thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. Moreover, the present invention also relates to methods of preventing joint damage in a subject having hyperuricemia and who has gout by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.